Last 2,426
Change Today +1.00 / 0.04%
Volume 11.3K
KMDA On Other Exchanges
Symbol
Exchange
Tel Aviv
As of 3:51 AM 09/1/14 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$2,413
Previous Close
$2,425
Day High
$2,427
Day Low
$2,407
52 Week High
03/3/14 - $6,200
52 Week Low
07/16/14 - $2,211
Market Cap
872.7M
Average Volume 10 Days
64.2K
EPS TTM
$-0.28
Shares Outstanding
36.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. Its respiratory disease products, including Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-1 antitrypsin deficiency; and Bramitob to manage chronic pulmonary infection. The company’s immunoglobulin products include KamRAB for prophylaxis against rabies infection; KamRho(D)IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; Snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. In addition, it provides critical care products, such as Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of proper level in the patient’s blood plasma. Further, the company offers Heparin Lock Flush to maintain patency of indwelling IV catheter; Human Transferrin for diagnostic assays and cell cultures; and Kamacaine 0.5% used as anesthesia or analgesia for surgery, obstetrical procedures, and diagnostic and therapeutic procedures, as well as spinal anesthesia for surgery. Additionally, it offers coagulation factors, including Factor VIII, Factor IX, and Bupivacaine. The company also develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary disease, graft-versus-host diseases, and transplantations. It has a collaboration partnership with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States and Europe; and distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

289 Employees
Last Reported Date: 03/26/14
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $1.5M
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $232.0K
Senior Vice President of Quality & Regulatory...
Total Annual Compensation: $174.0K
Vice President of Clinical Development & IP
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the Year Ending December 31, 2014

Kamada Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the second quarter of 2014 of $15.8 million compared with $16.1 million for the second quarter of 2013.  For the second quarter of 2014, the Company reported an operating loss of $7.9 million compared with operating income of $1.7 million for the second quarter of 2013.  Net loss for the second quarter of 2014 was $8.4 million or $0.23 per share, compared with net income of $0.89 million or $0.03 per diluted share for the same period in 2013.  Adjusted net loss for the second quarter of 2014 was $7.4 million compared with adjusted net income of $2.7 million for the same period in 2013. Adjusted EBITDA for the second quarter of 2014 was negative $6.2 million compared with positive $4.2 million for the second quarter of 2013. Loss before taxes on income was $8,351,000 against income of $902,000 a year ago. Net cash used in operating activities was $3,733,000 against $3,833,000 a year ago. Purchase of property and equipment was $919,000 against $1,473,000 a year ago. Total revenue for the first half of 2014 of $29.0 million compared with $28.7 million for the first half of 2013. Operating loss for the first six months of 2014 of $10.6 million compared with operating income of $0.35 million for the first six months of 2013. Net loss for the first half of 2014 was $11.5 million or $0.32 per share, compared with a net loss of $1.1 million or $0.04 per share for the same period in 2013. Adjusted EBITDA for the first six months of 2014 was negative $7.2 million, compared with positive $3.9 million for the same period last year. Loss before taxes on income was $11,450,000 against $1,109,000 a year ago. Net cash used in operating activities was $5,279,000 against $3,333,000 a year ago. Purchase of property and equipment was $1,535,000 against $2,747,000 a year ago. Adjusted net loss was $9,389,000 against income of $890,000 a year ago. For the year ending December 31, 2014, Kamada expects total revenue to be between $70 million and $72 million, with revenue from its Distribution Segment projected to be between $25 million to $26 million and revenue from its Proprietary Products Segment to be between $45 million and $47 million.

Kamada Ltd. to Report Q2, 2014 Results on Aug 14, 2014

Kamada Ltd. announced that they will report Q2, 2014 results at 9:00 AM, Israel Standard Time on Aug 14, 2014

Kamada Ltd., Q2 2014 Earnings Call, Aug 14, 2014

Kamada Ltd., Q2 2014 Earnings Call, Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 2,426.00 +1.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €35.60 EUR +0.175
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.